Kiprime Research Wins Largest-Ever Non-Clinical Primate Study Contract Since Its Establishment

On February 19, KiPrime Research, a subsidiary of BioToxtech and the No. 1 toxicology testing institution in Korea, announced that it has won the largest-ever non-clinical primate study contract since its establishment.

K Prime Research.

The contract is worth 2.45 million dollars (about 3.5 billion won), exceeding 25% of the previous year's sales. In 2022, KiPrime Research built a non-clinical primate testing facility in Osong, Chungcheongbuk-do that meets global standards. It obtained Good Laboratory Practice (GLP) certification for repeated-dose toxicity studies in non-clinical primates in 2023 and GLP certification for cardiovascular safety pharmacology studies in non-clinical primates in 2025.

In line with the growing demand for biopharmaceuticals, KiPrime Research is offering differentiated technologies such as liver and heart biopsy services, specialized administration for ophthalmic diseases, and immunoassay services. It has also established a dedicated TFT to internalize alternative testing method (NAMs) technologies, and is designing and building service roadmaps for each technology through collaboration with government ministries and participation in private consortia.

The BioToxtech Group provides end-to-end non-clinical services across the entire preclinical spectrum, including high-quality toxicity and efficacy studies using non-clinical primates, rodents, and non-rodents, bioanalytical services, and laboratory animal sales, all for new drug development. KiPrime Research is currently preparing for listing on the KOSDAQ market.

CEO Kim Dongil said, "This contract is a case in which we directly penetrated the U.S. market, which can be regarded as the standard for global drug approvals, and it is highly meaningful in that KiPrime Research's competitiveness has been officially recognized," adding, "This year, we aim to achieve order intake of more than 30 billion won and to raise the proportion of overseas contracts to over 50%, and thereby leap forward as a truly global contract research organization (CRO)."